Researchers unveiled a genetic editing method that uses small nuclear RNAs instead of CRISPR. This approach produced fewer ...

Northwestern scientists have developed a new nanostructure that supercharges CRISPR’s ability to safely and efficiently enter cells, potentially unlocking its full power to treat genetic diseases. By ...

Horses with genomic edits to make them run faster have been banned from polo, but a zoo of CRISPR-edited animals is gaining ...

Stanford Medicine researchers have developed an artificial intelligence tool to help scientists better plan gene-editing ...

CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...

When brain development gets off to a bad start, the consequences are lifelong. One example is a condition called SCN2A ...

Researchers engineered and screened dozens of base editors to precisely target a single mutation without editing other portions of the DNA.

Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...

CRISPR Therapeutics AG (NASDAQ: CRSP) is one of the best emerging technology stocks to buy right now. On September 3, Bank of ...

The evolutionary blueprint for hands was borrowed in part from a much older genetic plan for our nether regions, a new study ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...